Romiplostim scFv-Transferrin Fusion for Barrier Transit and Cell Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Many antibodies face challenges in crossing biological barriers such as the blood-brain barrier and blood-eye barrier, and entering cancerous cells, reducing their efficacy and necessitating the Fc region for immune responses that are not always necessary.
Innovation Solution
A single-chain variable fragment (scFv) is designed to retain antigen-binding properties without the Fc region, conjugated with the N-methyl lobe of transferrin protein to enhance transcytosis, using environment-sensitive linkers for targeted delivery and release within specific cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the Fc region is retained in the antibody structure, then immune effector functions are enhanced, but the antibody cannot effectively cross biological barriers such as the blood-brain barrier and blood-eye barrier
Solution Approach 1:
The antibody is segmented into its functional components: the scFv region retains antigen-binding capability while the Fc region is removed. This segmentation allows the antigen-binding fragment to cross biological barriers independently, while immune effector functions can be reconstituted separately if needed through fusion with other domains or cellular mechanisms.
Solution Approach 2:
The Fc region is extracted from the complete antibody structure to create a minimized scFv fragment. This extraction removes the size limitation that prevents crossing of biological barriers while preserving the essential antigen-binding function. The scFv can then traverse barriers like the blood-brain barrier and blood-eye barrier that are inaccessible to full-length antibodies.
2Length of moving object
If the antibody molecule size is reduced to scFv, then penetration across biological barriers is improved, but the circulation time and stability are reduced
Solution Approach 1:
The small scFv fragment is merged with larger carrier molecules such as albumin or PEG (polyethylene glycol) chains. This merging increases the hydrodynamic radius and molecular weight of the scFv, thereby extending its circulation half-life in the bloodstream. The carrier acts as a protective shell that reduces renal clearance while allowing the scFv to maintain its ability to cross biological barriers.
Solution Approach 2:
The antibody fragment is constructed as a composite structure combining the scFv antigen-binding domain with stabilizing and size-increasing components such as albumin fusion proteins or PEGylated moieties. This composite construction provides both the small size needed for barrier penetration and the extended circulation time provided by the larger carrier components.
3Device complexity
If the Fc region is removed to create scFv, then manufacturing complexity is reduced, but the ability to mediate immune responses is lost
Solution Approach 1:
The scFv acts as an intermediary that delivers the antigen-binding function to target sites that would be inaccessible to full antibodies. For applications requiring immune response mediation, the scFv can be fused with Fc domains or other effector modules, creating a chimeric structure that combines the manufacturing simplicity of scFv with the immune-mediated capabilities of Fc-containing constructs when needed.
Solution Approach 2:
The antibody structure is optimized with local quality by including only the scFv region where antigen-binding functionality is required, while omitting the Fc region where manufacturing complexity would be increased. This local optimization allows simplified manufacturing for applications that do not require immune effector functions, while providing an option to add Fc domains locally if immune mediation becomes necessary.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The scFv-conjugate achieves enhanced delivery across biological barriers, reduces off-target effects, and prolongs circulation time, ensuring specific and efficient therapeutic action.
Implementation Method 1
Many of these antibodies cross cell walls that can be challenging, reducing their efficacy, such as antibodies crossing the blood-brain barrier, the blood-eye barrier and also entering cancerous cells, among many other situations where transcytosis promotion can increase their efficacy
Implementation Method 2
using environment-sensitive linkers for targeted delivery and release within specific cells
Data Source
AI summary
The efficacy and indication of romiplostim do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.